ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Eris Lifesciences has filed its annual Secretarial Compliance Report for the financial year ended March 31, 2026, as required under SEBI LODR Regulation 24(A). The report, issued by Practicing Company Secretary Ravi Kapoor, confirms broad compliance across multiple SEBI regulations including LODR, ICDR, Takeover, Share Based Employee Benefits, and Insider Trading regulations. One deviation was noted: the appointment of Independent Director Rajeev Dalal occurred 85 days after the previous director's term expired on December 18, 2025, which violated Regulation 17(1) regarding board composition requirements. The company paid a fine of Rs. 65,000 plus GST to each stock exchange. Management stated the delay was due to thorough identification, evaluation, due diligence, and approval processes needed to select a qualified candidate in the company's long-term interest. All other compliance areas including secretarial standards, policies, website disclosures, director qualifications, related party transactions, and insider trading norms were found satisfactory.
Minor regulatory non-compliance with no lasting shareholder impact. The company has paid fines, completed the appointment, and maintains good overall compliance standing. This routine filing should not materially affect the stock.